FDA Greenlights Generics for NASCOBAL Nasal Vitamin B12 Spray
Published Date: 4/9/2025
Notice
Summary
The FDA says NASCOBAL nasal spray wasn’t taken off the market because of safety or effectiveness problems. This means the spray stays approved, and generic versions can keep getting the green light if they follow the rules. Patients and pharmacies can keep counting on this nasal spray without any interruptions or extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Keeps NASCOBAL Approval
The FDA determined that NASCOBAL (cyanocobalamin) nasal spray, 0.5 mg/spray, was not withdrawn from sale for reasons of safety or effectiveness. Because of that finding, the FDA will not start procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this product and will continue to approve ANDAs that refer to it so long as they meet legal and regulatory requirements.
Patients’ Access and Costs Unchanged
You can keep relying on NASCOBAL (cyanocobalamin) nasal spray, 0.5 mg/spray, because the FDA found it was not withdrawn for safety or effectiveness. The FDA says approvals for ANDAs that refer to this product will continue, and the spray’s availability should continue without interruptions or extra costs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
Previous / Next Documents
Previous: 2025-06042, Notice of Public Meeting of the Maryland Advisory Committee to the U.S. Commission on Civil Rights
The Maryland Advisory Committee to the U.S. Commission on Civil Rights is holding its first public meeting online via Zoom. This meeting is for the new committee members to get together, discuss their goals, and start working on civil rights issues affecting Maryland residents. Everyone interested can join in, and there’s no cost to attend.
Next: 2025-06044, Determination That ETHYOL (Amifostine) for Injection, 500 Milligrams/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA checked and confirmed that ETHYOL (amifostine) 500 mg injection wasn’t taken off the market because of safety or effectiveness problems. This means drug companies can keep making and selling generic versions of ETHYOL as long as they follow the rules. Patients and healthcare providers can keep counting on this medicine without any interruptions or extra costs.